Purpose: Radionuclide therapy is increasingly seen as a promising option to target minimal residual disease. Copper-67, scandium-47 and terbium-161 have a medium-energy β(-) emission which is similar to that of lutetium-177, but offer the advantage of having diagnostic partner isotopes suitable for pretreatment imaging. The aim of this study was to compare the efficacy of (67)Cu, (47)Sc and (161)Tb to irradiate small tumors.
Methods: The absorbed dose deriving from a homogeneous distribution of (67)Cu, (47)Sc or (161)Tb in water-density spheres was calculated with the Monte Carlo code CELLDOSE. The diameters of the spheres ranged from 5 mm to 10 µm, thus simulating micrometastases or single tumor cells. All electron emissions, including β(-) spectra, Auger and conversion electrons were taken into account. Because these radionuclides differ in electron energy per decay, the simulations were run assuming that 1 MeV was released per µm(3), which would result in a dose of 160 Gy if totally absorbed.
Results: The absorbed dose was similar for the three radionuclides in the 5-mm sphere (146-149 Gy), but decreased differently in smaller spheres. In particular, (161)Tb delivered higher doses compared to the other radionuclides. For instance, in the 100-µm sphere, the absorbed dose was 24.1 Gy with (67)Cu, 14.8 Gy with (47)Sc and 44.5 Gy with (161)Tb. Auger and conversion electrons accounted for 71% of (161)Tb dose. The largest dose differences were found in cell-sized spheres. In the 10-µm sphere, the dose delivered by (161)Tb was 4.1 times higher than that from (67)Cu and 8.1 times that from (47)Sc.
Conclusion: (161)Tb can effectively irradiate small tumors thanks to its decay spectrum that combines medium-energy β(-) emission and low-energy conversion and Auger electrons. Therefore (161)Tb might be a better candidate than (67)Cu and (47)Sc for treating minimal residual disease in a clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955060 | PMC |
| http://dx.doi.org/10.7150/thno.15132 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methodology for measuring photonuclear reaction cross sections with an electron accelerator based on Bayesian analysis.
Appl Radiat Isot
June 2024
Department of Chemistry, Biochemistry, and Pharmaceutical Sciences (DCBP), University of Bern, 3012, Bern, Switzerland.
Accurate measurements of photonuclear reaction cross sections are crucial for a number of applications, including radiation shielding design, absorbed dose calculations, reactor physics and engineering, nuclear safeguard and inspection, astrophysics, and nuclear medicine. Primarily motivated by the study of the production of selected radionuclides with high-energy photon beams (mainly Ac, Sc, and Cu), we have established a methodology for the measurement of photonuclear reaction cross sections with the microtron accelerator available at the Swiss Federal Institute of Metrology (METAS). The proposed methodology is based on the measurement of the produced activity with a High Purity Germanium (HPGe) spectrometer and on the knowledge of the photon fluence spectrum through Monte Carlo simulations.
View Article and Find Full Text PDFIAEA Activities on Cu, Re, Sc Theranostic Radionuclides and Radiopharmaceuticals.
Curr Radiopharm
December 2021
Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna International Centre, PO Box 100, 1400, Vienna, Austria.
Despite interesting properties, the use of Cu, Re and Sc theranostic radionuclides in preclinical studies and clinical trials is curtailed by their limited availability due to a lack of widely established production methods. An IAEA Coordinated Research Project (CRP) was initiated to identify important technical issues related to the production and quality control of these emerging radionuclides and related radiopharmaceuticals, based on the request from IAEA Member States. The international team worked on targetry, separation, quality control and radiopharmaceutical aspects of the radionuclides obtained from research reactors and cyclotrons leading to preparation of a standard recommendations for all Member States.
View Article and Find Full Text PDFTherapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018).
Molecules
February 2019
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Ludovico Ariosto, 35-44121 Ferrara, Italy.
Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field.
View Article and Find Full Text PDFCalculation of productions of medical Pb, Au, Re, Ag, Pd, Y, Sr, Kr, As, Cu, Cu, Sc and P nuclei used in cancer therapy via phenomenological and microscopic level density models.
Appl Radiat Isot
February 2019
Department of Physics, Bülent Ecevit University, Turkey. Electronic address:
In the present study, we have widely investigated the production of nuclei used in cancer therapy for both phenomenological and microscopic level density models via TALYS and EMPIRE codes. To estimate the production of the radioisotope, we calculated the cross-section curves of the reaction and the integral yield curves for nine level density models using the cross-sections and the mass-stopping powers acquired from X-PMSP program in the particle beam current of 1 μA and irradiation time 1 h. To discuss the obtained results on the basis of the cross-sections and the integral yields curves, the results were compared with the experimental data and the recommended data in the literature.
View Article and Find Full Text PDFTherapeutic Radiometals Beyond Lu and Y: Production and Application of Promising α-Particle, β-Particle, and Auger Electron Emitters.
J Nucl Med
September 2017
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSA, Switzerland
In recent years, new α-particle-, β-particle-, and Auger electron-emitting radiometals-such as Cu, Sc, Ho, Tb, Tb, Pb/Bi, Ac, and Bi-have been produced and evaluated (pre)clinically for therapeutic purposes. In this short review article, the most important routes of production of these radiometals are critically discussed, as are examples of their application in preclinical and clinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!